| Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| private:mithrapharmaceuticals-2 | 1456363 | May 30th, 2019 12:00AM | Mithra | 5.7K | 214.00 | Open | Biotechnology | May 29th, 2019 08:46PM | May 29th, 2019 08:46PM | Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women’s health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO centre (more info : www.mithracdmo.com). Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. | Open | women's health, pharmaceutical development, R&D, contract manufacturing, CDMO | Open | Rue Saint-Georges 5 | Liège | Liège | BE | 4000 | Mithra Pharmaceuticals | |||
| private:mithrapharmaceuticals-2 | 1456363 | Nov 7th, 2017 12:00AM | Mithra | 2.6K | 158.00 | Open | Pharmaceuticals | Nov 7th, 2017 05:53PM | Nov 7th, 2017 05:53PM | Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women’s health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO centre (more info : www.mithracdmo.com). Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. | Mithra Pharmaceuticals | |||||||||||
| private:mithrapharmaceuticals-2 | 1456363 | Nov 1st, 2017 12:00AM | Mithra | 2.6K | 158.00 | Open | Pharmaceuticals | Nov 1st, 2017 05:35AM | Nov 1st, 2017 05:35AM | Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women’s health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO centre (more info : www.mithracdmo.com). Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. | Mithra Pharmaceuticals |